Symptoms reported by gastrointestinal stromal tumour (GIST) patients on imatinib treatment: combining questionnaire and forum data
Sign Up to like & getrecommendations! Published in 2022 at "Supportive Care in Cancer"
DOI: 10.1007/s00520-022-06929-3
Abstract: Treatment with the tyrosine kinase inhibitor (TKI) imatinib in patients with gastrointestinal stromal tumours (GIST) causes symptoms that could negatively impact health-related quality of life (HRQoL). Treatment-related symptoms are usually clinician-reported and little is known… read more here.
Keywords: gist patients; forum; treatment; forum data ... See more keywords